Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Ironwood missed quarterly expectations: It reported adjusted earnings of $0.31 per share versus the $0.32 consensus estimate, while revenue of $113.04 million also fell short of the $114.84 million forecast.
• LINZESS remained the key growth driver: U.S. sales rose 14% year over year to $282.3 million, and the company raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion following expanded FDA approval for pediatric constipation patients.
• Management increased full-year guidance and advanced its pipeline: Revenue guidance rose to $460 million–$485 million and adjusted EBITDA guidance to above $310 million, while enrollment began in the Phase III STARS-2 trial for apraglutide.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01), FiscalAI reports. The business had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%.

Here are the key takeaways from Ironwood Pharmaceuticals' conference call:

• LINZESS delivered strong momentum: Q2 U.S. net sales rose 14% year over year to $282.3 million, supported by mid-single-digit prescription growth and improved net pricing. Ironwood raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion, implying growth of more than 30% and a return to blockbuster status.
• The FDA approved LINZESS for functional constipation in pediatric patients aged two and older, making it the only prescription therapy approved for this age group and expanding the brand’s addressable patient population.
• Ironwood initiated active enrollment in the confirmatory Phase III STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure. Management believes the once-weekly therapy’s efficacy, tolerability, and potential to reduce parenteral-support dependence could support a best-in-class profile, though enrollment remains an execution priority.
• Q2 GAAP net income was $51 million and adjusted EBITDA was $83 million; full-year revenue guidance increased to $460 million–$485 million and adjusted EBITDA guidance to above $310 million. The company repaid $200 million of convertible notes and expects gross debt below $300 million and leverage below 1x by year-end.
• R&D spending is expected to rise in the second half as STARS-2 enrollment and site activation ramp, with modestly higher SG&A also anticipated. The ultimate expense increase will depend on how quickly additional trial sites are brought online.

Ironwood Pharmaceuticals Stock Performance

IRWD traded up $0.06 during midday trading on Friday, reaching $4.32. The company had a trading volume of 1,842,560 shares, compared to its average volume of 2,179,845. Ironwood Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $5.78. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $3.97. The stock has a market cap of $704.41 million, a PE ratio of 5.61 and a beta of 0.20.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the firm's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider directly owned 313,680 shares of the company's stock, valued at $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Julie Mchugh sold 21,571 shares of the company's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director directly owned 250,749 shares in the company, valued at $935,293.77. This represents a 7.92% decrease in their position. The disclosure for this sale is available in the SEC filing. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Large investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC increased its stake in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 3,406 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Ironwood Pharmaceuticals by 7.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company's stock valued at $259,000 after buying an additional 5,598 shares during the period. Public Employees Retirement System of Ohio lifted its position in Ironwood Pharmaceuticals by 11.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 67,888 shares of the biotechnology company's stock worth $229,000 after buying an additional 7,120 shares during the last quarter. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 14.0% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 59,617 shares of the biotechnology company's stock worth $201,000 after buying an additional 7,322 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Ironwood Pharmaceuticals by 3.5% during the third quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company's stock worth $292,000 after buying an additional 7,611 shares during the period.

Analysts Set New Price Targets

IRWD has been the subject of a number of analyst reports. Zacks Research lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Weiss Ratings reissued a "sell (d+)" rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. Finally, Wall Street Zen cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source